定量质谱解析一例临界抗凝血酶缺乏症
一例反复妊娠丢失女性筛查遗传性易栓症时抗凝血酶活性临界偏低,诊断不确定;用基于质谱的检测在分子水平鉴定出杂合p.Pro73Leu突变(抗凝血酶「Basel」),该突变增加静脉血栓栓塞和产科并发症风险。本病例说明传统诊断可能漏诊,质谱蛋白质诊断有助于精准诊断。
要点
- 抗凝血酶活性临界偏低时诊断不确定,传统一线活性检测敏感性不足可能漏诊。
- 质谱检测可在分子水平鉴定抗凝血酶变异体,本例为杂合p.Pro73Leu(抗凝血酶「Basel」)。
- 该突变增加静脉血栓栓塞和产科并发症风险,需结合分子诊断明确。
核心结论
- 传统抗凝血酶活性检测可能漏诊,质谱蛋白质诊断可分子层面明确变异体并支持精准诊断。
研究设计与样本
- 单病例报告:一例反复妊娠丢失女性筛查遗传性易栓症,抗凝血酶活性临界偏低,采用基于质谱的检测进行分子特征分析。
主要发现
- 质谱检测在分子水平鉴定出杂合p.Pro73Leu突变,即抗凝血酶「Basel」。
- 该突变增加静脉血栓栓塞和产科并发症风险。
临床怎么用
- 抗凝血酶活性临界偏低且诊断不确定时,可考虑质谱蛋白质诊断以明确变异体。
- 分子诊断信息有助于实验室和临床医生 unambiguous 诊断并推动精准诊断。
局限性
- 单病例报告,不能推广至所有抗凝血酶缺乏症筛查场景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antithrombin deficiency diagnostics by first-line activity tests suffer from a lack of sensitivity sometimes resulting in diagnostic uncertainty. We here present a case of a woman with recurrent pregnancy loss who was screened for inherited thrombophilia. Antithrombin activity was borderline low, resulting in uncertainty about the correct diagnosis. Using a mass spectrometry-based test, the antithrombin protein of the patient was characterized at the molecular level and a heterozygous p.Pro73Leu mutation was identified. The mutation, also known as antithrombin "Basel," increases the risk of venous thromboembolism and obstetric complications. This case is illustrative of current antithrombin deficiency screening, in which diagnoses may be missed by traditional diagnostics. Next-generation protein diagnostics by mass spectrometry provides molecular insight into the proteoforms present in vivo. This information is essential for laboratory specialists and clinicians to unambiguously diagnose patients and will aid in evolving healthcare from traditional to precision diagnostics.
引用
- Kruijt M, van der Pol LM, Eikenboom J, et al. Unraveling a borderline antithrombin deficiency case with quantitative mass spectrometry. J Thromb Haemost. 2021. PMID: 34653293. doi:10.1111/jth.15553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。